Stephen V. Liu
Impact in
- Oncology top 0.2%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
- Pancreatic and Hepatic Oncology Research
- Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations
Papers in
- Oncology 139
- Lung Cancer Research Studies 59
- Cancer Immunotherapy and Biomarkers 33
- HER2/EGFR in Cancer Research 20
- Peptidase Inhibition and Analysis 19
-
- Lung Cancer Treatments and Mutations 99
- Co-authors
- Giuseppe Giaccone (22 shared papers)Deepa Suresh Subramaniam (10 shared papers)Chul Kim (25 shared papers)Anish Thomas (1 shared paper)Lori J. Wirth (4 shared papers)Raffaele Califano (8 shared papers)Aaron Scott Mansfield (7 shared papers)Marina Chiara Garassino (7 shared papers)
- Journals
- Annals of Oncology (36 papers)Journal of Thoracic Oncology (18 papers)Lung Cancer (12 papers)Clinical Cancer Research (9 papers)Clinical Lung Cancer (9 papers)
- Partner nations
- United StatesGermanyFrance
In The Last Decade
Stephen V. Liu
265 papers receiving 14.0k citations
Stephen V. Liu's Hit Papers
Peers
Comparison fields: 5 of 155
- Oncology 7.8k
- Pulmonary and Respiratory Medicine 3.9k
- Cancer Research 1.6k
- Pathology and Forensic Medicine 1.1k
- Otorhinolaryngology 257
Countries citing papers authored by Stephen V. Liu
This map shows the geographic impact of Stephen V. Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen V. Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen V. Liu more than expected).
Fields of papers citing papers by Stephen V. Liu
This network shows the impact of papers produced by Stephen V. Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen V. Liu. The network helps show where Stephen V. Liu may publish in the future.
Co-authors
The 25 scholars most cited alongside Stephen V. Liu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 283 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 2693 |
| 2 | Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials Hit paper breakdown → | 2019 | 1330 |
| 3 | Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1) Hit paper breakdown → | 2017 | 671 |
| 4 | Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) Hit paper breakdown → | 2021 | 614 |
| 5 | Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study Hit paper breakdown → | 2017 | 559 |
| 6 | COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study Hit paper breakdown → | 2020 | 484 |
| 7 | Emerging Epidemic of Hepatitis C Virus Infections Among Young Nonurban Persons Who Inject Drugs in the United States, 2006–2012 Hit paper breakdown → | 2014 | 426 |
| 8 | Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study Hit paper breakdown → | 2021 | 328 |
| 9 | Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study Hit paper breakdown → | 2018 | 319 |
| 10 | What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC) Hit paper breakdown → | 2016 | 262 |
| 11 | 2015 | 257 | |
| 12 | 2000 | 243 | |
| 13 | 2000 | 234 | |
| 14 | 2015 | 195 | |
| 15 | 2019 | 184 | |
| 16 | 2020 | 183 | |
| 17 | 2018 | 163 | |
| 18 | 2020 | 147 | |
| 19 | Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial Hit paper breakdown → | 2022 | 136 |
| 20 | 2021 | 127 |
About Stephen V. Liu
Stephen V. Liu is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Epidemiology and Molecular Biology, having authored 283 papers that have together received 14.4k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (99 papers), Lung Cancer Research Studies (59 papers), Cancer Immunotherapy and Biomarkers (33 papers), Cancer Genomics and Diagnostics (29 papers), Neuroendocrine Tumor Research Advances (22 papers), HER2/EGFR in Cancer Research (20 papers), Cancer therapeutics and mechanisms (19 papers) and Peptidase Inhibition and Analysis (19 papers). The work is most often cited by research in Oncology (7.8k citations), Pulmonary and Respiratory Medicine (3.9k citations), Cancer Research (1.6k citations), Pathology and Forensic Medicine (1.1k citations) and Otorhinolaryngology (257 citations). Stephen V. Liu has collaborated with scholars based in United States, Germany and France. Frequent co-authors include Giuseppe Giaccone, Deepa Suresh Subramaniam, Chul Kim, Anish Thomas, Lori J. Wirth, Raffaele Califano, Aaron Scott Mansfield, Marina Chiara Garassino, Leora Horn and Martin Reck. Their work appears in journals such as Annals of Oncology, Journal of Thoracic Oncology, Lung Cancer, Clinical Cancer Research and Clinical Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.